A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Status:
Completed
Trial end date:
2019-12-09
Target enrollment:
Participant gender:
Summary
Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose]
vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in
a statistically significant effect on the tics in participants with TS.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.